Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets (Unaudited)

v3.20.2
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents [note 5] $ 22,393 $ 16,664
Prepaid expenses and other assets 1,669 670
Total current assets 24,062 17,334
Restricted cash [note 5] 50 50
Property and equipment, net 50 57
Right-of-use assets [note 7] 193 329
Other assets 308 187
License agreement [note 3 and 4] 1,920 2,087
Goodwill [note 4] 1,034 1,034
Total assets 27,617 21,078
Current liabilities:    
Accounts payable 326 859
Accrued liabilities other 360 304
Accrued clinical liabilities 93 387
Accrued compensation 940 1,116
Current portion of long-term obligations [note 7] 129 203
Total current liabilities 1,848 2,869
Long-term obligations [note 7] 94 159
Total liabilities 1,942 3,028
Commitments and contingencies [note 7]
Stockholders' equity:    
Common stock, $0.001 par value, 150,000,000 shares authorized, 3,616,414 issued and outstanding at September 30, 2020 and 1,474,258 issued and outstanding at December 31, 2019, respectively. 74 41
Additional paid-in capital 81,307 63,709
Accumulated deficit (55,710) (45,704)
Accumulated other comprehensive income 4 4
Total stockholders' equity 25,675 18,050
Total liabilities and stockholders' equity 27,617 21,078
Series A Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value
Series B Convertible Preferred Stock [Member]    
Stockholders' equity:    
Convertible preferred stock, value